drugset / Trial / NCT00515268

Endotoxin Challenge Study For Healthy Men and Women

NCT00515268

Phase 1 Completed 37 enrolled GlaxoSmithKline
RandomizedParallel-groupDiagnostic

Summary

The proposed study will examine the effect of pre-treatment with inhaled GSK256066 using a lung inflammation model induced by bronchoscopic instillation of bacterial endotoxin (lipopolysaccharide, LPS) in healthy volunteers.Data from this study will be used to support GSK256066 dose selection for future studies in COPD patients.

Timeline

Start
2007-09-27
Primary completion
2008-04-23
Completion
2008-04-23

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK256066 Small molecule 25 ug Inhaled
Subject GSK256066 Small molecule 87.5 ug Inhaled